We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · September 09, 2021

Dabrafenib Plus Trametinib in BRAF V600E–Mutant mNSCLC

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer: Updated 5-Year Survival Rates and Genomic Analysis
J Thorac Oncol 2021 Aug 26;[EPub Ahead of Print], D Planchard, B Besse, HJM Groen, SMS Hashemi, J Mazieres, TM Kim, E Quoix, PJ Souquet, F Barlesi, C Baik, LC Villaruz, RJ Kelly, S Zhang, M Tan, E Gasal, L Santarpia, BE Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading